HK$ 223
Key Takeaways
Risk factor
High price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Duality Biotherapeutics, Inc. operates as a clinical stage company. It focuses on the development of next generation antibody-drug conjugate therapeutics and duality immune toxin antibody conjugate therapeutic. The company was founded by Zhu Zhong Yuan on July 3, 2019 and is headquartered in Shanghai, China.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is trading at neutral levels on P/FCF.
Data is available to registered users only
Target Price
The average target price of 9606.HK is 419 and suggests 94% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Data is available to registered users only